These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 23743818

  • 1. Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex.
    Cappellano AM, Senerchia AA, Adolfo F, Paiva PM, Pinho R, Covic A, Cavalheiro S, Saba N.
    Childs Nerv Syst; 2013 Dec; 29(12):2301-5. PubMed ID: 23743818
    [Abstract] [Full Text] [Related]

  • 2. Everolimus tablets for patients with subependymal giant cell astrocytoma.
    Turner SG, Peters KB, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA.
    Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
    [Abstract] [Full Text] [Related]

  • 3. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
    Mateos-González ME, López-Laso E, Vicente-Rueda J, Camino-León R, Fernández-Ramos JA, Baena-Gómez MA, Peña-Rosa MJ.
    Rev Neurol; 2014 Dec 01; 59(11):497-502. PubMed ID: 25418144
    [Abstract] [Full Text] [Related]

  • 4. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
    Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN.
    N Engl J Med; 2010 Nov 04; 363(19):1801-11. PubMed ID: 21047224
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S.
    Lancet; 2013 Jan 12; 381(9861):125-32. PubMed ID: 23158522
    [Abstract] [Full Text] [Related]

  • 6. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M, Flanagan D, Mowat D, Kennedy SE, Chopra M, Lawson JA.
    J Pediatr; 2014 May 12; 164(5):1195-200. PubMed ID: 24518170
    [Abstract] [Full Text] [Related]

  • 7. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Anak O, Niolat J, Jozwiak S.
    Lancet Oncol; 2014 Dec 12; 15(13):1513-1520. PubMed ID: 25456370
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Fogarasi A, De Waele L, Bartalini G, Jozwiak S, Laforgia N, Verhelst H, Petrak B, Pedespan JM, Witt O, Castellana R, Crippa S, Gislimberti G, Gyorsok Z.
    BMC Neurol; 2016 Aug 08; 16():126. PubMed ID: 27502586
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus.
    Arroyo MS, Krueger DA, Broomall E, Stevenson CB, Franz DN.
    Pediatr Neurol; 2017 Jul 08; 72():81-85. PubMed ID: 28511812
    [Abstract] [Full Text] [Related]

  • 16. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Major P.
    Aging (Albany NY); 2011 Mar 08; 3(3):189-91. PubMed ID: 21415462
    [Abstract] [Full Text] [Related]

  • 17. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    Weidman DR, Pole JD, Bouffet E, Taylor MD, Bartels U.
    Pediatr Blood Cancer; 2015 Oct 08; 62(10):1754-60. PubMed ID: 25929843
    [Abstract] [Full Text] [Related]

  • 18. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
    Bissler JJ, Franz DN, Frost MD, Belousova E, Bebin EM, Sparagana S, Berkowitz N, Ridolfi A, Kingswood JC.
    Pediatr Nephrol; 2018 Jan 08; 33(1):101-109. PubMed ID: 28993887
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.